A podcast on medicine, oncology, & health policy. Host: Vinay Prasad, MD MPH from University of California San Francisco. Tweet your feedback to @Plenary_Session or e-mail plenarysessionpodcast@gmail.com
…
continue reading
Screening/ Drug efficacy/ Sotorasib/ Adaura and moreتوسط Plenary Session
…
continue reading
My UCSF lecture on driver mutation lung cancerتوسط Plenary Session
…
continue reading
We break down the best studies from ASCOتوسط Plenary Session
…
continue reading
1
Critical Appraisal - My 2 hour ASCO lecture - Day 2 version
1:54:09
1:54:09
در پخش در آینده
در پخش در آینده
لیست ها
پسندیدن
دوست داشته شد
1:54:09
Critical Appraisal - My 2 hour ASCO lecture - Day 2 version by Plenary Sessionتوسط Plenary Session
…
continue reading
What you need to know in advance of ASCOتوسط Plenary Session
…
continue reading
Should trials have carbon footprint as an endpoint?توسط Plenary Session
…
continue reading
My grand rounds; Beta blockers post MISingle center vs multicenter RCTMasksBoosters and moreتوسط Plenary Session
…
continue reading
I crossover SM podcast; Harvard med students video, Justice curriculum, Masking half the yearتوسط Plenary Session
…
continue reading
Patient advocates, Pharma funding, and is MRD a suitable endpointتوسط Plenary Session
…
continue reading
5 reasons that is a bad ideaتوسط Plenary Session
…
continue reading
Another flawed quality metric. Reviewing the NEJM paper "Beta-Blockers After Myocardial Infarction and Preserved Ejection Fraction".توسط Plenary Session
…
continue reading
They are shittyتوسط Plenary Session
…
continue reading
Another flawed study Keynote 564. Pembro in adjuvant RCCتوسط Plenary Session
…
continue reading
What happens when doctors run unethical studies?توسط Plenary Session
…
continue reading
Does car T cause secondary AML?We discussتوسط Plenary Session
…
continue reading
We talk about 2023 cancer trialsتوسط Plenary Session
…
continue reading
Goodman and I discuss ash updates.My myeloma talkhttps://www.youtube.com/watch?v=jAz84yCnfjQتوسط Plenary Session
…
continue reading